Views Differ On How Lab-Developed Tests Fit In FDA Companion Dx Guidance
This article was originally published in The Pink Sheet Daily
Some test kit makers say FDA needs to revise the draft issued this summer to state more plainly its intention to require clearance or approval for lab-developed companion diagnostics.
You may also be interested in...
A Center for Devices and Radiological Health representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.
The head of FDA’s diagnostics office is hopeful that draft guidance governing laboratory-developed tests will be issued by year-end, but cautioned that the process is taking more time than expected.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.